Forte Biosciences Management
Management criteria checks 1/4
Forte Biosciences' CEO is Paul A. Wagner, appointed in Jan 2018, has a tenure of 6.83 years. total yearly compensation is $1.45M, comprised of 42.7% salary and 57.3% bonuses, including company stock and options. directly owns 5.31% of the company’s shares, worth $1.21M. The average tenure of the management team and the board of directors is 3 years and 2.3 years respectively.
Key information
Paul A. Wagner
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 42.7% |
| CEO tenure | 6.8yrs |
| CEO ownership | 5.3% |
| Management average tenure | 3yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate
Jul 17
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?
Mar 14Large Forte Biosciences shareholder scolds company board of directors
Aug 24We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely
Aug 17Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Aug 16Forte Biosciences large shareholders make demands for company's future
Jul 07We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully
Dec 23Forte Biosciences files for $300M mixed shelf offering
May 28Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?
Mar 13Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Jan 19
Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis
Dec 18Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Nov 25Forte Biosciences readies equity offering
Oct 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$34m |
| Jun 30 2024 | n/a | n/a | -US$36m |
| Mar 31 2024 | n/a | n/a | -US$32m |
| Dec 31 2023 | US$1m | US$620k | -US$31m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$24m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$1m | US$590k | -US$14m |
| Sep 30 2022 | n/a | n/a | -US$12m |
| Jun 30 2022 | n/a | n/a | -US$17m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$5m | US$590k | -US$22m |
| Sep 30 2021 | n/a | n/a | -US$23m |
| Jun 30 2021 | n/a | n/a | -US$20m |
| Mar 31 2021 | n/a | n/a | -US$49m |
| Dec 31 2020 | US$777k | US$453k | -US$46m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | n/a | n/a | -US$39m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$525k | US$350k | -US$4m |
Compensation vs Market: Paul A.'s total compensation ($USD1.45M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Paul A.'s compensation has increased whilst the company is unprofitable.
CEO
Paul A. Wagner (54 yo)
6.8yrs
Tenure
US$1,450,175
Compensation
Dr. Paul A. Wagner, CFA, Ph.D. has been the Senior Vice President of Corporate Strategy & Development and Chief Business Officer at CANbridge Life Sciences Ltd. since October 16, 2017. Dr. Wagner leads CAN...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 6.8yrs | US$1.45m | 5.31% $ 1.2m | |
| Chief Financial Officer | 4.7yrs | US$722.98k | 0.57% $ 129.2k | |
| Chief Medical Clinician & Director | less than a year | US$61.73k | 0% $ 0 | |
| Chief Operating Officer | 2.5yrs | no data | no data | |
| Chief Technical Officer | 3yrs | no data | no data |
3.0yrs
Average Tenure
62yo
Average Age
Experienced Management: FBRX's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 7.8yrs | US$1.45m | 5.31% $ 1.2m | |
| Chief Medical Clinician & Director | 2.7yrs | US$61.73k | 0% $ 0 | |
| Independent Director | 1.8yrs | US$104.30k | 0.41% $ 92.9k | |
| Independent Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | US$50.80k | no data | |
| Member of Scientific Advisory Board & Independent Director | 2.5yrs | US$62.73k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$97.73k | 0.27% $ 61.9k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 2yrs | US$62.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.3yrs
Average Tenure
60yo
Average Age
Experienced Board: FBRX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.